573 POSTER Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumors with mutated EGFR

Plummer, R. ; Vidal, L. ; Li, L. ; Shaw, H. ; Perrett, R. ; Shahidi, M. ; Amelsberg, A. ; Temple, G. ; Calvert, H. ; de Bono, J.

European journal of cancer supplements, 2006-11, Vol.4 (12), p.173-174 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível